You are here: Industry Insights > UCB

News List

UCB acquires gene therapy specialist Handl Therapeutics pharmatimes
November 12, 2020
UCB has announced its acquisition of Belgium-based gene therapy company Handl Therapeutics, in a move that will bolster its pipeline programmes, capabilities and platforms in the gene therapy space.
UCB acquires new campus to support UK operations pharmatimes
October 22, 2020
Belgian pharma company UCB has agreed to acquire a new campus to further support its operations in the UK.
UCB’s Cimzia bags EU label extension pharmatimes
August 07, 2020
The European Medicines Agency (EMA) has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adult patients with axial spondyloarthritis (axSpA) at a reduced maintenance dose.
UCB Announces Alzheimer's Disease Treatment Coloration with Roche americanpharmaceuticalreview
August 05, 2020
UCB announced an agreement to enter into a world-wide, exclusive license agreement with Roche and Genentech, a member of the Roche Group, for the global development and commercialization of UCB0107 in Alzheimer's Disease (AD).
Roche and UCB partner to develop antibody therapy for Alzheimer’s pharmaceutical-technology
July 31, 2020
Roche and its unit Genentech have agreed to a global, exclusive licence agreement with Belgian company UCB to develop and commercialise an antibody treatment, UCB0107, for Alzheimer’s disease.
UCB Acquires Engage Therapeutics for $125M contractpharma
June 08, 2020
Gains Staccato Alprazolam in Phase II development as a single-use epileptic seizure rescue therapy.
Amgen-UCB’s Evenity receives EC approval to treat osteoporosis pharmaceutical-technology
December 16, 2019
Amgen and UCB have received the European Commission (EC) approval for Evenity (romosozumab) to treat severe osteoporosis in postmenopausal women at high fracture risk.
UCB Trial Achieves Endpoints ContractPharma
December 11, 2019
Phase III study met its co-primary and secondary endpoints demonstrating superiority of bimekizumab to Abbvie’s Humira in plaque psoriasis
Samsung BioLogics, UCB sign third drug manufacturing deal biospectrumasia
August 01, 2019
SBL will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy
Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal contractpharma
August 01, 2019
The CDMO will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy.

Previous page 1 2 3 4 5 6 Next page